Randomised Trial of Anti-CD20 in C4d+ Chronic Allograft Nephropathy
Phase of Trial: Phase IV
Latest Information Update: 21 Aug 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms RituxiCAN-C4
- 15 Aug 2017 Status changed from active, no longer recruiting to completed.
- 09 Jan 2017 Planned End Date changed from 1 Jan 2018 to 1 Apr 2017.
- 04 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.